Highlights and Quick Summary
Current Net Cash/Marketcap of AbbVie Inc. is $0.416 (as of December 30, 2020)
- Net Cash/Marketcap for the quarter ending September 29, 2021 was $0.359 (a -2.84% decrease compared to previous quarter)
- Year-over-year quarterly Net Cash/Marketcap decreased by -13.69%
- Annual Net Cash/Marketcap for 2020 was $0.416 (a 103.28% increase from previous year)
- Annual Net Cash/Marketcap for 2019 was $0.204 (a -9.96% decrease from previous year)
- Annual Net Cash/Marketcap for 2018 was $0.227 (a 29.27% increase from previous year)
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Net Cash/Marketcap of AbbVie Inc.
Most recent Net Cash/Marketcapof ABBV including historical data for past 10 years.Interactive Chart of Net Cash/Marketcap of AbbVie Inc.
AbbVie Inc. Net Cash/Marketcap for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2021 | $0.0 | $0.0 | $0.0 | – | – |
| 2020 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2019 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2018 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2017 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2016 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2015 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2014 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2013 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2012 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2011 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
| 2010 | – | – | – | – | $0.0 |
Business Profile of AbbVie Inc.
Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.